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ABSTRACT
Cutaneous B cell lymphoma (CBCL) is a lymphoproliferative disorder of neoplastic B cell of the 
skin with a wide range of clinical manifestations. Commonly, the clinical features of CBCL are 
plaques, nodules, or ulcerative lesions. Skin is one of the common sites for extra-nodal lympho-
mas in patients with AIDS and B cell type is less common than T cell type. Only recently, the exist-
ence of B cell lymphomas presenting clinically in the skin without evidence of extra-cutaneous 
involvement has been accepted as primary CBCL. Here, we are presenting 5 patients with cutane-
ous involvement in the setting of HIV/AIDS disease. Two of them were primary cutaneous non-
Hodgkin lymphomas. All were CBCL; 3 were immunoblastic, 1 was plasmablastic, and the other 
was a Burkitt lymphoma. We analyzed the epidemiological, clinical, virological, and immunologi-
cal characteristics of this group of patients. 
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INTRODUCTION
Non-Hodgkin´s lymphomas (NHL) are fre-
quent malignancies in AIDS patients. The 
estimated related risk of NHL associated 
with HIV infection is 100 times greater than 
in general population, and the risk increases 
with the progressive immunosuppression 
related with retrovirus.1-4 More than 90% 
of HIV-associated NHL is derived from 
B cells and the majority is high grade. Ex-
tranodal presentation is most frequent in 
HIV-seropositive patients than in general 
population and occurs in 70% to 80% of 
the cases. Cutaneous B cell lymphoma is 
an infrequent group of neoplasms that ac-
cording to the World Health Organization 
(WHO) and the European Organization for 
Research and Treatment of Cancer (EORTC) 
classification,5 form a specific group of non 
Hodgkin’s lymphoma (NHL). Primary cuta-
neous B-cell lymphomas are a heterogene-
ous group of B-cell extranodal lymphomas 
arising in the skin, without evidence of ex-
tracutaneous disease at the time of diagno-
sis.6 In some cases they represent the initial 
manifestation of a systemic lymphoma. 
The aim of this study was to present the 
epidemiological, clinical, histopathological, 
immunological, and virological findings in 
five patients with HIV/AIDS disease and 
NHL with cutaneous involvement.
CASE REPORTS
We analyzed retrospectively all cases of 
lymphomas with cutaneous involvement 
occurring in human immunodeficiency vi-
rus (HIV) infected patients from the files 
of the HIV/AIDS Division of the Infectious 
Diseases “Francisco J. Muñiz” Hospital in 
Argentina, during the years 2005 and 2006. 
Diagnosis of cutaneous NHL was made by 
biopsy of skin lesions and histopathological 
examination. 
We defined NHL and B symptoms by the 
Ann Arbor staging system.2 Immunostain-
ing with monoclonal antibodies was per-
formed in all biopsy smears to determine 
the immunophenotype of the lymphoma. 
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The clinical staining procedure included: bone marrow 
biopsies in four patients and total body computed tom-
ography (CT) scan (brain, thorax, abdomen, and pelvis) 
which was performed in all patients. 
The Epstein-Barr virus (EBV) genome in tumour 
cells was detected by immunohistochemistry (IHQ) tests 
for the latent membrane protein type 1 (LMP-1) and by 
in situ hybridization (ISH) for the EBERs. Polymerase 
chain reaction was performed for detection of human 
herpesvirus-8 (HHV-8) DNA in patient with AIDS re-
lated plasmablastic lymphoma.
During the period 2005 to 2006 there were 3,556 ad-
missions in the HIV/AIDS division of our hospital. For-
ty three patients (1.2%) had diagnosis of AIDS related 
lymphomas; 5 of them (11.6%) initially presented with 
cutaneous compromise. All of them were males; median 
Table 1. Main clinical findings in patients with lymphomas and skin involvement
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Sex Male Male Male Male Male
Age (years) 44 42 34 34 36
Risk factor for Intravenous Homosexual Heterosexual Bisexual IDU
HIV infection drug user (IDU) 
Localization Systemic with  Single perianal Initiall Single perianal Disseminated
 facial cutaneous cutaneous (chest cutaneous cutaneous  cutaneous 
 lesions wall and scalp) lesion lesion lesions
Bone marrow NR Negative Positive Negative Negative
infiltration 
Brain, thorax,  Liver compromise Normal Costal and cranial Normal Costal and  
abdomen and    compromise   neighbour  
pelvis CT scans     pulmonary  
     parenchymal  
     involvement
HCV Positive Negative Negative Negative Positive
CD4 (cells / µL) 78 48 153 54 56
Phenotype B B B B B
Histological Subtype Burkitt Immunoblastic Immunoblastic Immunoblastic Plasmablastic
EBV Negative NR Negative Positive Positive  
    (HHV-8+) 
Treatment No HAART alone No Chemotherapy Chemotherapy 
    plus HAART plus HAART
Survival 20 days 24 months  16 days 18 months 6 months
15. NR: not realized
Figure 1: Multiple and nodular cutaneous lesions in a patient 
with Burkitt’s lymphoma.
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age was 36 years. All patients presented with B symp-
toms and nodular and/or tumours lesions with different 
cutaneous locations (Figure 1, 2 and 3). In two patients, 
lymphoma was the first AIDS-defining illness. Extracu-
taneous involvement was confirmed by biopsy in three 
patients (60%). The other two were classified as primary 
cutaneous lymphomas (patients 2 and 4). Median count 
of CD4+ T-cell at the time of neoplasm diagnosis was
56 cells/µL. All lymphomas were extranodal and of high 
grade and B phenotype. Three of them were immuno-
blastic, one plasmablastic, and one Burkitt lymphoma 
Figure 2: A large tumoral lesion on the right shoulder corre-
sponding to the diagnosis of plasmablastic lymphoma..
Figure 3: Multiple and reddish tumoral lesions on chest wall 
in a patient with plasmablastic lymphoma with cutaneous 
involvement..
Figure 4: Atypical lymphoid infiltrate with large and multinu-
cleated cells with little or unapparent cytoplasm, the majority 
containing several and small nucleoli. Between the atypical 
elements we can see reactive histiocites situated within clear 
spaces, with “starred sky” aspect. The mitotic index was high 
with numerous cellular rests of picnotic nuclei, indicating the 
great cellular spare of this tumour. The histopathological di-
agnosis was Burkitt´s lymphoma.. (Figure 4). The EBV genome in the atypical cells was 
detected in 2 patients (one with immunoblastic and the 
other with plasmablastic lymphoma). The HHV-8 ge-
nome was also detected in the patient with plasmablas-
tic lymphoma. Two patients could not receive chemo-
therapy due to rapid progression of illness or presence 
of other opportunistic diseases. One patient with peri-
anal cutaneous lymphoma received antiretroviral treat-
ment (ART) only. The other two were treated with ART 
plus chemotherapy based on CHOP (cyclofosfamide, 
doxorubicin, vincristine, and prednisone) completion 
of six cycles. The patient with plasmablastic lymphoma 
died after 6 months of being diagnosed with neoplasm. 
The other two are still alive with a complete remission of 
neoplasm disease, after 18 and 24 months, respectively. 
The main clinical features are summarised in Table 1.
DISCUSSION
Patients infected with HIV are at increased risk of de-
veloping NHL, including primary central nervous sys-
tem lymphoma (PCNSL). Their frequency and clinical 
aggressive presentation has led to consider them as a 
criterion for stage C of AIDS, according to the Centers 
for Disease Control (CDC) and prevention classifica-
tion. AIDS-related NHL (AIDS-NHLs) are mostly, but 
not all, of high-grade and B phenotype, as in the series 
we presented.7 Cutaneous lymphomas are characterized 
by an initial accumulation of mononuclear, mostly lym-
phocytic cells in the skin.8 
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Primary cutaneous lymphomas represent 5% to 10% 
of total extranodal NHL and are the second in frequency 
after lymphomas arising gastrointestinal tract.9 Cutane-
ous B-cell lymphomas are less frequent than primary 
cutaneous T-cell and include about 20% to 25% of all 
primary cutaneous lymphomas.5 They include subtypes 
with an indolent course and evolution; and others, as 
the primary diffuse large B-cell lymphoma (DLBCL), 
more aggressive. DLBCL are divided in two subcatego-
ries, including the centroblastic and the immunoblastic 
lymphomas of the previous Kiel classification.9 In the 
serie of Beylot-Barry et al. that included 21 cases of cu-
taneous lymphomas, the 10 B-cell cutaneous lympho-
mas were immunoblastic or centroblastic lymphomas. 
Four of them expressed the EBV genome.10 In our se-
ries, DLBCL subtype immunoblastic include three of the 
five cases (60%) with one plasmablastic and one Burkitt 
lymphoma.
Clinical presentation of cutaneous NHL includes 
single or multiple subcutaneous nodes, dermis papules, 
and ulcerative and infiltrative lesions. Specific cutaneous 
lesions are more frequents in NHL in comparison with 
the Hodgkin disease (HD). Patients with NHL showed 
cutaneous involvement in 15% to 20% of cases and in 
5% to 10% of them, skin lesions are the first manifesta-
tion of the disease. In contrast, only 5% to 10% of pa-
tients with HD present cutaneous lesions.5,9,10  
Cutaneous compromise in NHL is an expression of 
advanced neoplasm disease. The five patients of our se-
ries had diagnosis of advanced HIV/AIDS disease with 
severe immunosuppression and low CD4 T - cell counts 
at the time of neoplasm diagnosis.10 
EBV appears to play a major role in certain AIDS-
NHL, such as AIDS-related DLBCL, including PCNSL 
and AIDS anaplastic NHL. EBV is strongly associated 
with the pathogenesis of these subtypes of lymphomas. 
The recently identified HHV-8 is related with the patho-
genesis of AIDS-primary effusion lymphoma and oral 
plasmablastic lymphoma.11,12 EBV could be identified by 
ISH and IHQ in 2 patients of this series; in one of them 
also with HHV-8 (plasmablastic lymphoma).    
The number of lesions, single versus multiple, is a 
prognostic factor in primary cutaneous B-cell lympho-
mas.13 In this series, the patients with single perianal 
skin lesions had a significant better survival as there was 
no evidence of disseminated disease (in spite of the co-
existence of another neoplasm, Kaposi’s sarcoma, in one 
of them) after 18 and 24 months of the diagnosis. The 
therapy was based on six cycles of chemotherapy fol-
lowed by HAART in one of them and HAART alone in 
the other, respectively.
In conclusion, lymphomas with cutaneous compro-
mise are uncommon in HIV-infected patients. The most 
important diagnosis elucidation is to determine wheth-
er the cutaneous tumour is a primary cutaneous lym-
phoma or when it represents cutaneous metastases of an 
aggressive systemic AIDS-related NHL.14 
In our experience, early diagnosis followed by specif-
ic therapy based on highly active antiretroviral therapy 
(HAART) plus chemotherapy improves the prognosis 
and the survival of patients with AIDS and cutaneous 
compromise by NHL.
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